TY - JOUR
T1 - Assessment and pathophysiology of microvascular disease
T2 - Recent progress and clinical implications
AU - Masi, Stefano
AU - Rizzoni, Damiano
AU - Taddei, Stefano
AU - Widmer, Robert Jay
AU - Montezano, Augusto C.
AU - Lüscher, Thomas F.
AU - Schiffrin, Ernesto L.
AU - Touyz, Rhian M.
AU - Paneni, Francesco
AU - Lerman, Amir
AU - Lanza, Gaetano A.
AU - Virdis, Agostino
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2021/7/7
Y1 - 2021/7/7
N2 - The development of novel, non-invasive techniques and standardization of protocols to assess microvascular dysfunction have elucidated the key role of microvascular changes in the evolution of cardiovascular (CV) damage, and their capacity to predict an increased risk of adverse events. These technical advances parallel with the development of novel biological assays that enabled the ex vivo identification of pathways promoting microvascular dysfunction, providing novel potential treatment targets for preventing cerebral-CV disease. In this article, we provide an update of diagnostic testing strategies to detect and characterize microvascular dysfunction and suggestions on how to standardize and maximize the information obtained from each microvascular assay. We examine emerging data highlighting the significance of microvascular dysfunction in the development CV disease manifestations. Finally, we summarize the pathophysiology of microvascular dysfunction emphasizing the role of oxidative stress and its regulation by epigenetic mechanisms, which might represent potential targets for novel interventions beyond conventional approaches, representing a new frontier in CV disease reduction.
AB - The development of novel, non-invasive techniques and standardization of protocols to assess microvascular dysfunction have elucidated the key role of microvascular changes in the evolution of cardiovascular (CV) damage, and their capacity to predict an increased risk of adverse events. These technical advances parallel with the development of novel biological assays that enabled the ex vivo identification of pathways promoting microvascular dysfunction, providing novel potential treatment targets for preventing cerebral-CV disease. In this article, we provide an update of diagnostic testing strategies to detect and characterize microvascular dysfunction and suggestions on how to standardize and maximize the information obtained from each microvascular assay. We examine emerging data highlighting the significance of microvascular dysfunction in the development CV disease manifestations. Finally, we summarize the pathophysiology of microvascular dysfunction emphasizing the role of oxidative stress and its regulation by epigenetic mechanisms, which might represent potential targets for novel interventions beyond conventional approaches, representing a new frontier in CV disease reduction.
KW - Clinical manifestations
KW - Epigenetics
KW - Microvascular disease
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85104265017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104265017&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehaa857
DO - 10.1093/eurheartj/ehaa857
M3 - Review article
C2 - 33257973
AN - SCOPUS:85104265017
SN - 0195-668X
VL - 42
SP - 2590
EP - 2604
JO - European Heart Journal
JF - European Heart Journal
IS - 26
ER -